Decoding cell death signalling: Impact on the response of breast cancer cells to approved therapies.

Autor: Lozon L; College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates. Electronic address: U20104718@sharjah.ac.ae., Ramadan WS; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates. Electronic address: wframadan@sharjah.ac.ae., Kawaf RR; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates; College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates. Electronic address: U22103652@sharjah.ac.ae., Al-Shihabi AM; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates; College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates. Electronic address: U23103882@sharjah.ac.ae., El-Awady R; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates; College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates. Electronic address: relawady@sharjah.ac.ae.
Jazyk: angličtina
Zdroj: Life sciences [Life Sci] 2024 Apr 01; Vol. 342, pp. 122525. Date of Electronic Publication: 2024 Feb 27.
DOI: 10.1016/j.lfs.2024.122525
Abstrakt: Breast cancer is a principal cause of cancer-related mortality in female worldwide. While many approved therapies have shown promising outcomes in treating breast cancer, understanding the intricate signalling pathways controlling cell death is crucial for optimizing the treatment outcome. A growing body of evidence has unveiled the aberrations in multiple cell death pathways across diverse cancer types, highlighting these pathways as appealing targets for therapeutic interventions. In this review, we provide a comprehensive overview of the current state of knowledge on the cell death signalling mechanisms with a particular focus on their impact on the response of breast cancer cells to approved therapies. Additionally, we discuss the potentials of combination therapies that exploit the synergy between approved drugs and therapeutic agents targeting modulators of cell death pathways.
Competing Interests: Declaration of competing interest The authors declare that there is no conflict of interest regarding this work.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: